RODENSTOCK announces financial results for 2024
- By Editorial Team
The Rodenstock Group (“Rodenstock”) has announced its results for the financial year 2024 this week. Fueled by sustained growth in demand for the B.I.G. VISION® product portfolio for biometric lenses and MyConTM lenses for children, Rodenstock increased consolidated net sales to 512.4 million euros (2023: 506.1 million euros).
The 2024 financial year was characterized by ongoing geopolitical and economic challenges, the company said. Despite the uncertain market environment, Rodenstock achieved an adjusted EBITDA of EUR 128.6 million in 2024, an increase of 5.1% compared to the previous year.
The statement goes on to say that the consistent pursuit of the B.I.G. VISION® strategy has contributed to solid financial results. It has also strengthened the company’s position as a leading Med-Tech company and drove the paradigm shift in individual lenses. Since the market launch of MyConTM lenses in 2023, sales have increased by 62% worldwide in the last year. The lenses for children are designed to correct short-sightedness, ensure sharp vision and counteract the progression of myopia. Additionally, the successful launch of the DNEye® Scanner 3 emphasizes the company’s advanced technology and customer benefits.
The significant double-digit growth of Indo Optical and a notable increase in sales of the B.I.G. VISION® product portfolio for biometric lenses consolidated Rodenstock’s position in the ophthalmic lens sector.
Marcus Desimoni, CEO of the Rodenstock Group, said: “I would like to thank the entire team for another successful year, especially regarding great benefits for customers that result in very satisfied customers. With the strong performance of our B.I.G. VISION® portfolio, MyConTM lenses and the strategic launch of the DNEye® Scanner 3, we have reached key milestones in our strategy. These achievements provide a strong foundation for further growth.”
